Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 4 1Phase 1 1

Status

Completed 10Active not recruiting 4Not yet recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Capecitabine 25Oxaliplatin 24Paclitaxel 23Gemcitabine 21Cisplatin 21Fluorouracil 20Carboplatin 18Drug Therapy 17Docetaxel 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Injections 10Radiation 9Pemetrexed 9Magnetic Resonance Spectroscopy 9Bevacizumab 9toripalimab 8Cetuximab 8Surgical Procedures, Operative 7Specimen Handling 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6atezolizumab 6Topotecan 6Cyclophosphamide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Sirolimus × Clear all
NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
312 enrolled
Breast

Breast Neoplasms

NCT04736589 2021-02-03

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Peking Union Medical College

Phase 3 Not yet recruiting
270 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡